SG11201502989XA - Compositions and methods for treating proteinopathies - Google Patents
Compositions and methods for treating proteinopathiesInfo
- Publication number
- SG11201502989XA SG11201502989XA SG11201502989XA SG11201502989XA SG11201502989XA SG 11201502989X A SG11201502989X A SG 11201502989XA SG 11201502989X A SG11201502989X A SG 11201502989XA SG 11201502989X A SG11201502989X A SG 11201502989XA SG 11201502989X A SG11201502989X A SG 11201502989XA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- treating proteinopathies
- proteinopathies
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261722434P | 2012-11-05 | 2012-11-05 | |
| PCT/US2013/068242 WO2014071282A1 (en) | 2012-11-05 | 2013-11-04 | Compositions and methods for treating proteinopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201502989XA true SG11201502989XA (en) | 2015-05-28 |
Family
ID=49578599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201502989XA SG11201502989XA (en) | 2012-11-05 | 2013-11-04 | Compositions and methods for treating proteinopathies |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20150284472A1 (en) |
| EP (1) | EP2914281A1 (en) |
| JP (1) | JP2016503405A (en) |
| KR (1) | KR20150079751A (en) |
| CN (1) | CN104902923A (en) |
| AR (1) | AR093355A1 (en) |
| AU (1) | AU2013337354A1 (en) |
| BR (1) | BR112015009746A2 (en) |
| CA (1) | CA2889990A1 (en) |
| CL (1) | CL2015001157A1 (en) |
| CR (1) | CR20150216A (en) |
| EA (1) | EA201590880A1 (en) |
| HK (1) | HK1214521A1 (en) |
| IL (1) | IL238416A0 (en) |
| MA (1) | MA38144A1 (en) |
| MX (1) | MX2015005722A (en) |
| PH (1) | PH12015500879A1 (en) |
| SG (1) | SG11201502989XA (en) |
| TN (1) | TN2015000171A1 (en) |
| TW (1) | TW201427695A (en) |
| WO (1) | WO2014071282A1 (en) |
| ZA (1) | ZA201502618B (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3578195T3 (en) | 2008-06-26 | 2023-10-30 | Zevra Denmark As | Use of Hsp70 as a regulator of enzymatic activity |
| CA2817773A1 (en) | 2010-11-30 | 2012-06-07 | Orphazyme Aps | Methods for increasing intracellular activity of hsp70 |
| KR102582559B1 (en) | 2014-09-15 | 2023-09-26 | 제브라 덴마크 에이/에스 | Arimoclomol formulation |
| US10967073B2 (en) * | 2015-05-07 | 2021-04-06 | The Mclean Hospital Corporation | Glucocerebrosidase gene therapy for Parkinson's disease |
| SG11201901265SA (en) * | 2015-07-21 | 2019-03-28 | Univ Jefferson | Gene therapies for neurodegenerative disorders targeting ganglioside biosynthetic pathways |
| WO2017178029A1 (en) | 2016-04-13 | 2017-10-19 | Orphazyme Aps | Heat shock proteins and cholesterol homeostasis |
| CN109069496A (en) * | 2016-04-29 | 2018-12-21 | 奥菲泽米有限公司 | For treating the arimoclomol of glucocerebrosidase related disease |
| EP3264092A1 (en) * | 2016-07-01 | 2018-01-03 | Centogene AG | Use of lyso-gb1 as druggable target |
| WO2018027037A2 (en) * | 2016-08-03 | 2018-02-08 | University Of South Florida | Reelin compositions for treatment of neurological disorders |
| US20200276335A1 (en) * | 2017-10-03 | 2020-09-03 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| KR20200078512A (en) | 2017-10-03 | 2020-07-01 | 프리베일 테라퓨틱스, 인크. | Gene therapy for lysosomal disorders |
| KR20200078513A (en) | 2017-10-03 | 2020-07-01 | 프리베일 테라퓨틱스, 인크. | Gene therapy for lysosomal disorders |
| CN113005123A (en) * | 2017-10-23 | 2021-06-22 | 普利维尔治疗公司 | Gene therapy for neurodegenerative diseases |
| JP2021501135A (en) * | 2017-10-26 | 2021-01-14 | シャイア ヒューマン ジェネティック セラピーズ インコーポレイテッド | Formulation containing glucocerebrosidase and isofagomin |
| WO2019175883A1 (en) * | 2018-03-14 | 2019-09-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Detection of phospho-serine 129 alpha-synuclein in blood cells as a biomarker for synucleinopathies |
| EP3953378A1 (en) | 2019-04-10 | 2022-02-16 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| EP3986412A4 (en) | 2019-06-21 | 2023-11-15 | The Broad Institute, Inc. | Agents for reversing toxic proteinopathies |
| EP4192961A2 (en) | 2020-08-06 | 2023-06-14 | Fundacion para la Investigacion Medica Aplicada | Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy |
| IL303026A (en) | 2020-11-19 | 2023-07-01 | Zevra Denmark As | Processes for preparing arimoclomol citrate and intermediates thereof |
| CN112569354B (en) * | 2020-12-29 | 2022-06-10 | 四川大学华西医院 | Application of tau protein and gene thereof as drug target in preparation of drugs for treating diabetes |
| WO2023111336A1 (en) * | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Oligonucleotide gba agonists |
| WO2023111335A1 (en) * | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Oligonucleotides capable of increasing glucocerebrosidase expression |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
| EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ATE408012T1 (en) | 1991-12-02 | 2008-09-15 | Medical Res Council | PRODUCTION OF AUTOANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES |
| AU687829B2 (en) | 1993-06-24 | 1998-03-05 | Advec, Inc. | Adenovirus vectors for gene therapy |
| CA2173975C (en) | 1993-10-25 | 2007-06-12 | Richard J. Gregory | Recombinant adenoviral vector and methods of use |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| US6696248B1 (en) | 1995-08-18 | 2004-02-24 | Morphosys Ag | Protein/(poly)peptide libraries |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| US6924123B2 (en) | 1996-10-29 | 2005-08-02 | Oxford Biomedica (Uk) Limited | Lentiviral LTR-deleted vector |
| US6989264B2 (en) | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| ATE482275T1 (en) | 1999-07-02 | 2010-10-15 | Morphosys Ag | GENERATION OF SPECIFIC BINDING PARTNERS THAT BIND TO (POLY)PEPTIDES ENCODED BY GENOMIC DNA FRAGMENTS OR ESTS |
| DE60039766D1 (en) | 1999-08-09 | 2008-09-18 | Targeted Genetics Corp | TEROLOGIC NUCLEOTIDE SEQUENCE FROM A RECOMBINANT VIRAL VECTOR BY STRUCTURE OF THE SEQUENCE IN A WAY THAT BASE COUNTERATIONS ARISE WITHIN THE SEQUENCE |
| DE60117550T2 (en) | 2000-06-01 | 2006-12-07 | University Of North Carolina At Chapel Hill | DOUBLE-SIDED PARVOVIRUS VECTORS |
| WO2001097829A2 (en) | 2000-06-19 | 2001-12-27 | Genzyme Corporation | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US7446098B2 (en) * | 2003-02-18 | 2008-11-04 | Mount Sinai School Of Medicine Of New York University | Combination therapy for treating protein deficiencies |
| US7765583B2 (en) | 2005-02-28 | 2010-07-27 | France Telecom | System and method for managing virtual user domains |
| ES2387845T3 (en) * | 2006-06-23 | 2012-10-02 | Amicus Therapeutics, Inc. | Method for the treatment of neurological disorders by improving the activity of beta-glucocerebrosidase |
| HUE027278T2 (en) * | 2007-05-16 | 2016-11-28 | Brigham & Womens Hospital Inc | Treatment of synucleinopathies |
| US9845327B2 (en) | 2011-06-22 | 2017-12-19 | The General Hospital Corporation | Treatment of proteinopathies |
| CA2868484A1 (en) | 2012-03-28 | 2013-10-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Salicylic acid derivatives useful as glucocerebrosidase activators |
-
2013
- 2013-11-04 AU AU2013337354A patent/AU2013337354A1/en not_active Abandoned
- 2013-11-04 US US14/440,818 patent/US20150284472A1/en not_active Abandoned
- 2013-11-04 JP JP2015540845A patent/JP2016503405A/en not_active Abandoned
- 2013-11-04 BR BR112015009746A patent/BR112015009746A2/en not_active IP Right Cessation
- 2013-11-04 WO PCT/US2013/068242 patent/WO2014071282A1/en active Application Filing
- 2013-11-04 EA EA201590880A patent/EA201590880A1/en unknown
- 2013-11-04 SG SG11201502989XA patent/SG11201502989XA/en unknown
- 2013-11-04 CN CN201380069582.2A patent/CN104902923A/en active Pending
- 2013-11-04 MX MX2015005722A patent/MX2015005722A/en unknown
- 2013-11-04 EP EP13789690.8A patent/EP2914281A1/en not_active Withdrawn
- 2013-11-04 CA CA2889990A patent/CA2889990A1/en not_active Abandoned
- 2013-11-04 TW TW102139891A patent/TW201427695A/en unknown
- 2013-11-04 KR KR1020157013541A patent/KR20150079751A/en not_active Application Discontinuation
- 2013-11-04 MA MA38144A patent/MA38144A1/en unknown
- 2013-11-05 AR ARP130104033A patent/AR093355A1/en unknown
-
2015
- 2015-04-17 ZA ZA2015/02618A patent/ZA201502618B/en unknown
- 2015-04-20 PH PH12015500879A patent/PH12015500879A1/en unknown
- 2015-04-21 IL IL238416A patent/IL238416A0/en unknown
- 2015-04-28 CR CR20150216A patent/CR20150216A/en unknown
- 2015-04-30 CL CL2015001157A patent/CL2015001157A1/en unknown
- 2015-05-04 TN TNP2015000171A patent/TN2015000171A1/en unknown
-
2016
- 2016-03-07 HK HK16102536.9A patent/HK1214521A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201502618B (en) | 2016-01-27 |
| PH12015500879A1 (en) | 2015-06-29 |
| EA201590880A1 (en) | 2015-09-30 |
| KR20150079751A (en) | 2015-07-08 |
| TN2015000171A1 (en) | 2016-10-03 |
| CL2015001157A1 (en) | 2015-10-16 |
| US20150284472A1 (en) | 2015-10-08 |
| CN104902923A (en) | 2015-09-09 |
| AU2013337354A1 (en) | 2015-05-21 |
| JP2016503405A (en) | 2016-02-04 |
| CA2889990A1 (en) | 2014-05-08 |
| CR20150216A (en) | 2015-05-29 |
| HK1214521A1 (en) | 2016-07-29 |
| IL238416A0 (en) | 2015-06-30 |
| EP2914281A1 (en) | 2015-09-09 |
| AR093355A1 (en) | 2015-06-03 |
| TW201427695A (en) | 2014-07-16 |
| MA38144A1 (en) | 2018-08-31 |
| BR112015009746A2 (en) | 2017-08-15 |
| MX2015005722A (en) | 2016-01-12 |
| WO2014071282A1 (en) | 2014-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1214521A1 (en) | Compositions and methods for treating proteinopathies | |
| HK1209798A1 (en) | Compositions and methods for treating cancer | |
| EP2836482A4 (en) | Compositions and methods for treating cancer | |
| HK1251796A1 (en) | Methods and compositions for treating diabetes | |
| EP2890720A4 (en) | Compositions and methods for treating cancer | |
| IL269166A (en) | Methods and compositions for treating inflammation | |
| HK1215170A1 (en) | Methods and compositions for treating schizophrenia | |
| HK1209633A1 (en) | Compositions and methods for treating diabetes | |
| HUE044816T2 (en) | Compositions and methods for treating hair loss | |
| HK1208598A1 (en) | Methods and compositions for treating pain | |
| HK1216854A1 (en) | Compositions and methods for treating cancer | |
| EP2931280A4 (en) | Methods and compositions for inhibiting cnksr1 | |
| EP2863939A4 (en) | Compositions and methods for treatment vitiligo | |
| HK1211852A1 (en) | Methods and compositions for treating progesterone-dependent conditions | |
| HK1207561A1 (en) | Compositions and methods for treating hepatocellular cancer | |
| EP2841102A4 (en) | Methods and compositions for treating cancer | |
| EP2822593A4 (en) | Compositions and methods for treating cancer | |
| EP2800763A4 (en) | Compositions and methods for treating multiple sclerosis | |
| EP2865272A4 (en) | Plant-disease-control composition and plant-disease-control method |